Viatris, Inc. (VTRS)
|Net Income (ttm)||-2.05B|
|Ex-Dividend Date||Aug 23, 2021|
|Day's Range||13.91 - 14.10|
|52-Week Range||12.75 - 18.59|
|Price Target||20.15 (+44.5%)|
|Est. Earnings Date||Nov 8, 2021|
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agen... [Read more...]
Financial PerformanceFinancial Statements
According to 19 analysts, the average rating for Viatris stock is "Buy." The 12-month stock price forecast is 20.15, which is an increase of 44.55% from the latest price.
The mean of analysts' price targets for Viatris (VTRS) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...
Analysts are bullish about these bargains.
Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary
PITTSBURGH, Oct. 20, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) is proud to confirm that Express Scripts, a leading pharmacy benefit management organization, will list Viatris' interchangeable bio...
Cigna Corp's pharmacy benefit unit said on Wednesday it will prefer Viatris Inc and Biocon Biologics Ltd's insulin drug Semglee, a cheaper alternative to Sanofi SA's Lantus, on the list of medicines it ...
Wall Street's three main indexes are advancing this Thursday; treasury yields are dropping, and buying sentiment remains high. Viatris Inc. (NASDAQ: VTRS) shares are still not able to stabilize above $1...
Crashes and corrections are the perfect opportunity to buy great companies at a discount.
PITTSBURGH, Oct. 13, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2021 financial results on Monday, Nov. 8, before the open of the U.S. financial markets. Chief Ex...
PITTSBURGH, Oct. 11, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a new kind of global healthcare company, today announced that Fortune has named the company fifth out of 53 on its Change the World...
And these stocks also pay relatively high dividends.
Viatris Inc. ( VTRS , Financial) was formed by the combination of generic pharmaceutical company Mylan and Upjohn, Pfizer Inc.'s ( PFE , Financial) off-patent segment. Though the Mylan part of the combi...
Whether you're a growth or value investor, there's an income stock for all preferences.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc. and Encourages Inv...
LOS ANGELES--(BUSINESS WIRE)---- $VTRS #MYL--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc.
Analysts' loftiest price targets portend significant upside for these widely owned (and followed) stocks.
Viatris, Las Vegas Sands, and Take-Two Interactive are trailing the market in 2021. You should consider buying two of them but stay away from the third.
Wall Street's loftiest price targets suggest these income stocks could more than double.
It's kind of a boring stock. But analysts think that it could deliver not-so-boring growth.
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
You can invest in these solid stocks with a peace of mind.
With yields ranging from 2.3% to 10.1%, these income stocks can quickly build wealth for investors.
And their yields are both over 3%.
PITTSBURGH, Aug. 30, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the BofA Global Healthcare Conference on Wednesday, Septemb...